Atorvastatin    (DrugBank: Atorvastatin)

17 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎8
46悪性関節リウマチ8
49全身性エリテマトーデス6
51全身性強皮症2
58肥大型心筋症1
63特発性血小板減少性紫斑病1
79家族性高コレステロール血症(ホモ接合体)3
84サルコイドーシス1
88慢性血栓塞栓性肺高血圧症1
93原発性胆汁性胆管炎2
96クローン病3
160先天性魚鱗癬1
222一次性ネフローゼ症候群1
225先天性腎性尿崩症1
265脂肪萎縮症1
271強直性脊椎炎1
299嚢胞性線維症4

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01111656March 200715/3/2010Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bSWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)Relapsing-remitting Multiple SclerosisDrug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin groupUniversity Hospital Inselspital, BerneViollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, SwitzerlandCompleted18 Years67 YearsBoth28Phase 2Switzerland
2NCT00818103January 200631/12/2008Characteristic Study on Chinese Patients With Multiple SclerosisCharacteristic Study on Chinese Patients With Multiple SclerosisMultiple SclerosisDrug: atorvastatin;Drug: ß-interferon;Drug: EPOSun Yat-sen UniversityThird Affiliated Hospital, Sun Yat-Sen UniversityRecruitingN/A65 YearsBoth600N/AChina
3EUCTR2005-001009-25-IT16/07/200515/03/2006Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNAEfficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA Multiple sclerosis treatment
MedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: TORVAST*10CPR 10MG
INN or Proposed INN: Atorvastatin
Trade Name: TORVAST*10CPR 10MG
INN or Proposed INN: Atorvastatin
DR DIMENSIONE RICERCANULLNot RecruitingFemale: yes
Male: yes
Italy
4NCT00094172May 200514/10/2004Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisA Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)Multiple SclerosisDrug: Atorvastatin;Drug: PlaceboNational Institute of Allergy and Infectious Diseases (NIAID)Immune Tolerance Network (ITN)Completed18 Years55 YearsAll82Phase 2United States;Canada
5NCT00942591May 200517/7/2009Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1bEfficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.Multiple SclerosisDrug: Interferon beta 1b;Drug: AtorvastatinUniversity Hospital Inselspital, BerneCRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 BaselCompleted18 Years55 YearsBoth77Phase 2Switzerland
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00137176October 200426/8/2005EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisEARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple SclerosisMultiple SclerosisDrug: RebifUniversity of North Carolina, Chapel HillNULLCompleted18 Years60 YearsBoth30N/AUnited States
7NCT00103974July 200417/2/2005Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisA Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple SclerosisMultiple SclerosisBiological: BHT-3009-01Bayhill TherapeuticsNULLCompleted18 Years65 YearsBoth30Phase 1United States;Canada
8NCT00616187October 20035/2/2008Atorvastatin in Relapsing-Remitting Multiple SclerosisOral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: interferon beta treatment to add-on atorvastatin treatment;Drug: untreated to atorvastatin treatmentCharite University, Berlin, GermanyGerman Research Foundation;German Federal Ministry of Education and Research;PfizerCompleted18 Years55 YearsAll41Phase 2NULL

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04608344November 4, 202023/10/2020Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsA Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsRheumatoid ArthritisDrug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: FilgotinibGilead SciencesGalapagos NVRecruiting18 Years55 YearsAll30Phase 1United States
2NCT04056039August 14, 201821/6/2019Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis.Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.Cardiovascular Diseases;Arthritis, RheumatoidDrug: Atorvastatin;Drug: ColchicineHospital Central Dr. Ignacio Morones PrietoNULLCompleted18 YearsN/AAll60Phase 2Mexico
3ChiCTR-INR-170117722017-06-272017-06-28The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agentsThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents Rheumatoid Arthritistest group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group;Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated HospitalNULLRecruiting1865Bothtest group:80;Control group:40;China
4EUCTR2013-005524-42-NL10/03/201527/03/2014STAtins to Prevent Rheumatoid Arthritis (STAPRA)Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trial - STAtins to Prevent Rheumatoid Arthritis (STAPRA) Rheumatoid arthritis
MedDRA version: 19.0Level: PTClassification code 10039080Term: Rheumatoid factor positiveSystem Organ Class: 10022891 - Investigations;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Atorvastatin
Product Name: Atorvastatin
Product Code: C10AA05
INN or Proposed INN: ATORVASTATIN
ReadeNULLNot RecruitingFemale: yes
Male: yes
220Phase 4Netherlands
5NCT02219191August 201416/7/2014Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic DiseasesThe Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic DiseasesRheumatoid ArthritisDrug: puerarin tablet 50 mg;Drug: Atorvastatin tablet 20 mgChengdu PLA General HospitalNULLActive, not recruiting18 Years75 YearsAll150N/AChina
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01059864February 201028/1/2010Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid ArthritisRheumatoid ArthritisDrug: CP-690,550;Drug: Atorvastatin;Drug: Atorvastatin PlaceboPfizerNULLCompleted18 YearsN/AAll111Phase 2United States;Korea, Republic of
7EUCTR2006-006032-22-GB04/04/200726/02/2007TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RATRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RA Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their cholesterol-lowering properties, but possibly through anti-inflammatory and immunomodulatory effects. This trial will assess the hypothesis that atorvastatin is more effective than placebo in the primary prevention of cardiovascular events in patients with RA.University of ManchesterDudley Group of Hospitals NHS Trust Not Recruiting Female: yes
Male: yes
5350 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noUnited Kingdom
8NCT00356473March 200325/7/2006Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid ArthritisEffects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid ArthritisRheumatoid ArthritisDrug: AtorvastatinUniversity of California, Los AngelesNULLCompleted18 YearsN/ABoth20Phase 4NULL

49. 全身性エリテマトーデス [臨床試験数:827,薬物数:638(DrugBank:168),標的遺伝子数:108,標的パスウェイ数:191
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 827 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-INR-170114952017-05-252017-05-26The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosusThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus Primary mild to moderate systemic systemic lupus erythematosusImmunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.;The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyNULLRecruitingBothImmunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30;China
2ChiCTR-INC-170114972017-05-252017-05-26The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of moderate to severe activity systemic lupus erythematosusThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of moderate to severe activity systemic lupus erythematosus moderate to severe active systemic lupus erythematosusImmunomodulation combined with traditional DMARDS treatment group:Immunomodulation combined with traditional DMARDS group: On the basis of glucocorticoid and traditional DMARDS treatment, metformin hydrochloride tablets 250mg, 3 times / day, oral; atorvastatin tablets 10mg, 1 times / day; in the first 4 weeks , 12 weeks and 24 weeks to assess the SELSNA-SLEDAI score table,traditional DMARDS treatment group:Traditional DMARDS treatment group: the use of glucocorticoid and traditional DMARDS treatment. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyNULLPendingBothImmunomodulation combined with traditional DMARDS treatment group:60;traditional DMARDS treatment group:60;China
3NCT00519363September 200720/8/2007Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like ReceptorsStatins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors.Systemic Lupus ErythematosusDrug: atorvastatinThe Center for Rheumatic Disease, Allergy, & ImmunologySaint Luke's Health SystemCompleted18 Years60 YearsFemale15Phase 1/Phase 2United States
4NCT00432354March 20076/2/2007An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: atorvastatinBuddhist Tzu Chi General HospitalPfizerRecruiting16 Years80 YearsBoth40Phase 2/Phase 3Taiwan
5NCT00412841November 200218/12/2006Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus ErythematosusAVN Prevention With Lipitor in Lupus Erythematosus APLLE TrialAvascular NecrosisDrug: Atorvastatin;Procedure: MRI, Venipuncture;Drug: PlaceboNYU Langone HealthNULLTerminated18 Years75 YearsFemale43Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00120887April 200212/7/2005Lupus Atherosclerosis Prevention StudyLupus Atherosclerosis Prevention StudySystemic Lupus ErythematosusDrug: AtorvastatinJohns Hopkins UniversityAlliance for Lupus ResearchCompleted18 YearsN/ABoth200Phase 4United States

51. 全身性強皮症 [臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 466 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02370784February 201526/1/2015Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse SclerodermaThe Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic SclerosisSclerodermaDrug: atorvastatin;Drug: PlaceboRobyn T. Domsic, MD, MPHNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed18 Years70 YearsAll24Phase 2United States
2EUCTR2005-003775-21-GB14/08/200810/11/2005Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis - Atorvastatin in systemic sclerosisEffects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis - Atorvastatin in systemic sclerosis Systemic sclerosis (also termed 'scleroderma')Salford Royal Hospitals NHS TrustUniversity of ManchesterNot Recruiting Female: yes
Male: yes
36 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): yesUnited Kingdom

58. 肥大型心筋症 [臨床試験数:92,薬物数:126(DrugBank:35),標的遺伝子数:40,標的パスウェイ数:141
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 92 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00317967April 200724/4/2006Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the HeartStatin Induced Regression of Cardiomyopathy Trial - SirCatHypertrophic CardiomyopathyDrug: Atorvastatin;Drug: PlaceboUniversity of CalgaryHeart and Stroke Foundation of CanadaCompleted18 YearsN/ABoth22Phase 3Canada

63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132
Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 311 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03692754March 1, 202029/9/2018Atorvastatin in Management of Newly Diagnosed ITPA Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)Immune Thrombocytopenia;Purpura, ThrombocytopenicDrug: Atorvastatin 20mg;Drug: Atorvastatin 10mgShandong UniversityNULLRecruiting18 Years80 YearsAll30Phase 4China

79. 家族性高コレステロール血症(ホモ接合体) [臨床試験数:128,薬物数:105(DrugBank:29),標的遺伝子数:8,標的パスウェイ数:15
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03510715August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States
2NCT03885921October 25, 200020/3/2019Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Ezetimibe;Drug: Atorvastatin;Drug: SimvastatinMerck Sharp & Dohme Corp.NULLCompleted12 YearsN/AAll44Phase 3NULL
3NCT03884452May 3, 20006/3/2019Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial HypercholesterolemiaFamilial HypercholesterolemiaDrug: Atorvastatin;Drug: Simvastatin;Drug: Ezetimibe;Drug: Placebo for EzetimibeMerck Sharp & Dohme Corp.NULLCompleted12 YearsN/AAll50Phase 3NULL

84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 143 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00279708January 200618/1/2006Atorvastatin to Treat Pulmonary SarcoidosisAtorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled TrialSarcoidosis, PulmonaryDrug: Atorvastatin;Other: Placebo Oral TabletNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted18 Years70 YearsAll55Phase 2United States

88. 慢性血栓塞栓性肺高血圧症 [臨床試験数:145,薬物数:112(DrugBank:22),標的遺伝子数:13,標的パスウェイ数:52
Searched query = "Chronic thromboembolic pulmonary hypertension", "CTEPH", "Idiopathic chronic pulmonary thromboembolism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 145 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TNRC-080002632008-06-012008-12-18The study of the intervention with statin on PE and CTEPHThe study of the intervention with statin on PE and CTEPH pulmonary embolism and chronic thromboembolic pulmonary hypertensionGroup A:basic treatment + atorvastatin;Group B:basic treatment;Tongji Hospital of Tongji UniversityNULLCompleted1880BothGroup A:30;Group B:30;China

93. 原発性胆汁性胆管炎 [臨床試験数:230,薬物数:215(DrugBank:51),標的遺伝子数:34,標的パスウェイ数:107
Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 230 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00844402January 200613/2/2009Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary CirrhosisSafety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary CirrhosisPrimary Biliary Cirrhosis;HypercholesterolemiaDrug: AtorvastatinMedical University of GrazNULLCompleted18 Years70 YearsBoth40Phase 3Austria
2EUCTR2005-002160-28-AT23/09/200519/08/2005Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosisSafety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essential. Moreover, the study will answer the open question whether long-term treatment with statins may have potential beneficial effects on the course of PBC.Trade Name: Sortis
Product Name: Sortis 10 mg
INN or Proposed INN: Atorvastatin
Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and HepatologyNULLNot RecruitingFemale: yes
Male: yes
80Austria

96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-010163-16-GB05/06/200918/08/2009Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease - Bile salt manipulation in Crohn’s diseaseBile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease - Bile salt manipulation in Crohn’s disease Active Crohn's disease affecting the ileum
MedDRA version: 9.1 Level: LLT Classification code 10011406 Term: Crohn's ileitis
MedDRA version: 9.1 Level: LLT Classification code 10058815 Term: Crohn's disease acute episode
University College LondonNULLNot Recruiting Female: yes
Male: yes
13 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noUnited Kingdom
2EUCTR2005-000496-17-SE06/10/200624/02/2005Atorvastatin in moderat active Crohns diseaseAtorvastatin in moderat active Crohns disease Crohn's disease is an idiopathic chronic inflammatory bowel disease thought to result from inappropriate and ongoing activation of the mucosal immune system driven by the presence of normal luminal flora. It may affect the hole gastrointestinal tract, from mouth to rectum, with symptoms such as diarrhea, weight lose, malabsorption, abdominal pain and fever.Product Name: atorvastatinRegion SkåneNULLNot RecruitingFemale: yes
Male: yes
12Sweden
3NCT00454545October 200629/3/2007Atorvastatin in Moderate Active Crohns DiseaseCrohns DiseaseDrug: AtorvastatinSkane University HospitalNULLCompleted18 Years65 YearsBoth12Phase 2Sweden

160. 先天性魚鱗癬 [臨床試験数:32,薬物数:62(DrugBank:18),標的遺伝子数:15,標的パスウェイ数:107
Searched query = "Congenital ichthyosis", "Keratinopathic ichthyosis", "Epidermolytic ichthyosis", "Harlequin ichthyosis", "Congenital Ichthyosiform Erythroderma", "Foliate ichthyosis", "Ichthyosis syndrome", "Netherton syndrome", "Sjogren-Larsson syndrome", "Sjögren-Larsson syndrome", "Keratitis-ichtyosis-deafness syndrome", "Dorfman-Chanarin syndrome", "Neutral lipid storage disease", "NLSD", "Multiple sulfatase deficiency", "Austin disease", "Recessive X-linked ichthyosis", "RXLI", "X-linked recessive ichthyosis", "Ichthyosis, brittle hair, impaired intelligence, decreased fertility and short stature", "IBID", "Trichothiodystrophy", "Follicular ichthyosis", "Congenital hemidysplasia, ichthyosiform erythroderma or nevus, and limb defects syndrome", "CHILD syndrome", "Conradi-Hunermann-Happle syndrome", "Conradi-Hünermann-Happle syndrome", "CHHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 32 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs03118040925/12/201322/03/2019Treatment of the genetic defect of cholesterol biosynthetic pathway.Treatment of the genetic defect of cholesterol biosynthetic pathway by the topical application of statin and cholesterol. CHILD syndrome, Conradi syndrome, porokeratosis, atopic dermatitis, psoriasis, seborrheic dermatitis
Dermatitis and eczema
To patients, 1% atorvastatin/ 2% cholesterol lotion and/or 1% atorvastatin/ 2% cholesterol ointment, and/or 1% oxiconazole cream are topically applied on the skin. To healthy subjects, administration of atorvastatin or topical application of 1% atorvastatin/ 2% cholesterol is performed once to investigate drug metabolism.Kubo AkiharuNULLNot RecruitingNot applicableNot applicableBoth158Japan

222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00814255December 200822/12/2008Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed1 Year65 YearsAll32Phase 2United States;Canada

225. 先天性腎性尿崩症 [臨床試験数:12,薬物数:45(DrugBank:17),標的遺伝子数:30,標的パスウェイ数:63
Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 12 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02967653July 13, 201715/11/2016Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes InsipidusAtorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled TrialLithium Use, Nephrogenic Diabetes InsipidusDrug: AtorvastatinLady Davis InstituteNULLCompleted18 Years85 YearsAll60Phase 2Canada

265. 脂肪萎縮症 [臨床試験数:109,薬物数:164(DrugBank:59),標的遺伝子数:26,標的パスウェイ数:94
Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 109 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00017758June 200111/6/2001The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering DrugsThe Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase InhibitorsHIV Infections;HIV Seronegativity;LipodystrophyDrug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: EfavirenzNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years60 YearsBoth56Phase 1United States

271. 強直性脊椎炎 [臨床試験数:531,薬物数:343(DrugBank:66),標的遺伝子数:41,標的パスウェイ数:141
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 531 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-002860-19-NL07/01/201415/08/2013Cardiovascular risk in patients with Ankylosing SpondylitisThe risk of cardiovascular disease in Ankylosing Spondylitis; A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammation - AS risk Ankylosing SpondylitisAtherosclerotic cardiovascular disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Atorvastatin
Product Name: Atorvastatin
Product Code: 5057732
INN or Proposed INN: ATORVASTATIN
Other descriptive name: atorvastatin
AMCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022042-24-GB24/12/201025/10/2010A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa - RCT of Atorvastatin in Bronchiectasis in patients with PseudomonasA Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa - RCT of Atorvastatin in Bronchiectasis in patients with Pseudomonas The aim of this randomized double blind controlled study is to evaluate the efficacy of a 3 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis.
MedDRA version: 14.1Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Trade Name: Lipitor
Product Name: Atorvastatin
INN or Proposed INN: Atorvastatin
Other descriptive name: Lipitor
NHS LothianUniversity of EdinburghNot RecruitingFemale: yes
Male: yes
32Phase 4United Kingdom
2EUCTR2010-022040-20-GB17/12/201021/10/2010A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis - Randomised Controlled Trial of Atorvastatin in BronchiectasisA Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis - Randomised Controlled Trial of Atorvastatin in Bronchiectasis The aim of this randomised double blind controlled study to evaluate the efficacy of 6 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis
MedDRA version: 14.1 Level: PT Classification code 10006445 Term: Bronchiectasis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
NHS LothianUniversity of EdinburghNot Recruiting Female: yes
Male: yes
60 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): no Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): yesUnited Kingdom
3NCT01299194November 201021/10/2010Atorvastatin in Bronchiectasis in Patients With Pseudomonas AeruginosaA Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas AeruginosaBRONCHIECTASISDrug: ATORVASTATINUniversity of EdinburghNHS LothianCompleted18 Years80 YearsAll32Phase 4United Kingdom
4NCT01299181November 201021/10/2010A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis BronchiectasisA Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis BronchiectasisBronchiectasisDrug: AtorvastatinUniversity of EdinburghNHS LothianCompleted18 Years75 YearsBoth60Phase 4United Kingdom